{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["21(7)"],"submitter":["Kim SH"],"funding":["Bukwang Pharmaceuticals"],"pubmed_abstract":["<h4>Objective</h4>This study was performed to evaluate the efficacy and safety of lurasidone (160 mg/day) compared to quetiapine XR (QXR; 600 mg/day) in the treatment of acutely psychotic patients with schizophrenia.<h4>Methods</h4>Patients were randomly assigned to 6 weeks of double-blind treatment with lurasidone 160 mg/day (n=105) or QXR 600 mg/day (n=105). Primary efficacy measure was the change from baseline to week 6 in Positive and Negative Syndrome Scale (PANSS) total score and Clinical Global Impressions severity (CGI-S) score. Adverse events, body measurements, and laboratory parameters were assessed.<h4>Results</h4>Lurasidone demonstrated non-inferiority to QXR on the PANSS total score. Adjusted mean±standard error change at week 6 on the PANSS total score was -26.42±2.02 and -2"],"journal":["Psychiatry investigation"],"pagination":["762-771"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11298266"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy and Safety of Lurasidone vs. Quetiapine XR in Acutely Psychotic Patients With Schizophrenia in Korea: A Randomized, Double-Blind, Active-Controlled Trial."],"pmcid":["PMC11298266"],"pubmed_authors":["Youn H","Kim E","Kim CE","Lee J","Choi J","Lee KY","Kim M","Lee JS","Kim SG","Lee BJ","Jung SW","Chee HS","Kim SI","Kim SH","Won S","Kim WH","Cheon EJ","Kang N","Kim MH","Song HR","Oh HS","Lee HJ","Kim DH","Park JI","Kim HG","Lee SH","Roh S","Park DH","Paik JW","Cho SJ","Lee BO","Lee KU","Chang JG","Lee SY","Jung DU","Jung HY","Chung IW"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and Safety of Lurasidone vs. Quetiapine XR in Acutely Psychotic Patients With Schizophrenia in Korea: A Randomized, Double-Blind, Active-Controlled Trial.","description":"<h4>Objective</h4>This study was performed to evaluate the efficacy and safety of lurasidone (160 mg/day) compared to quetiapine XR (QXR; 600 mg/day) in the treatment of acutely psychotic patients with schizophrenia.<h4>Methods</h4>Patients were randomly assigned to 6 weeks of double-blind treatment with lurasidone 160 mg/day (n=105) or QXR 600 mg/day (n=105). Primary efficacy measure was the change from baseline to week 6 in Positive and Negative Syndrome Scale (PANSS) total score and Clinical Global Impressions severity (CGI-S) score. Adverse events, body measurements, and laboratory parameters were assessed.<h4>Results</h4>Lurasidone demonstrated non-inferiority to QXR on the PANSS total score. Adjusted mean±standard error change at week 6 on the PANSS total score was -26.42±2.02 and -2","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2025-04-18T22:38:43.143Z","creation":"2025-02-19T04:41:04.047Z"},"accession":"S-EPMC11298266","cross_references":{"pubmed":["39089702"],"doi":["10.30773/pi.2024.0052"]}}